Paget's Disease of Bone: Evidence for Complex Pathogenetic Interactions

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 5, 2012, Pages 619-641

  Chung, Pui Yan Jenny ^a   Van Hul, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Bisphosphonates; OPG; Osteosarcoma; Paget's disease of bone; RANK; RANKL; SQSTM1; VCP; Virus

Indexed keywords

ALENDRONIC ACID; BINDING PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; SEQUESTOME1; TILUDRONIC ACID; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; ARTICLE; AUTOPHAGY; BONE CANCER; CASR GENE; CLINICAL TRIAL (TOPIC); CSF1 GENE; DIARRHEA; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; ESOPHAGUS ULCER; ESR1 GENE; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GOLGA6A GENE; HUMAN; JAW OSTEONECROSIS; NONHUMAN; NUP205 GENE; OPTN GENE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PML GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; RIN3 GENE; RISK ASSESSMENT; RISK FACTOR; SCLERITIS; SOMATIC MUTATION; SQSTM1 GENE; STOMACH EROSION; STOMACH ULCER; SYSTEMATIC REVIEW; TM7SF4 GENE; TNFRSF11A GENE; TNFRSF11B GENE; UVEITIS; VCP GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; CELL CYCLE PROTEINS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OSTEITIS DEFORMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBMED;

EID: 84859423325     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.07.005     Document Type: Article

References (265)

1. McManus I.C. Sir James Paget's research into medical education. Lancet 2005, 366(9484):506-513.
2. Armas J.B., Pimentel F., Guyer P.B., Cooper C., Pye S.R., O'Neill T.W. Evidence of geographic variation in the occurrence of Paget's disease. Bone 2002, 30(4):649-650.
3. Barker D.J. The epidemiology of Paget's disease. Metab Bone Dis Relat Res 1981, 3(4-5):231-233.
4. Choma T.J., Kuklo T.R., Islinger R.B., Murphey M.D., Temple H.T. Paget's disease of bone in patients younger than 40 years. Clin Orthop Relat Res 2004, 418:202-204.
5. Cooper C., Schafheutle K., Dennison E., Kellingray S., Guyer P., Barker D. The epidemiology of Paget's disease in Britain: is the prevalence decreasing?. J Bone Miner Res 1999, 14(2):192-197.
6. Doyle T., Gunn J., Anderson G., Gill M., Cundy T. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002, 31(5):616-619.
7. Guanabens N., Garrido J., Gobbo M., Piga A.M., del Pino J., Torrijos A., et al. Prevalence of Paget's disease of bone in Spain. Bone 2008, 43(6):1006-1009.
8. Poor G., Donath J., Fornet B., Cooper C. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006, 21(10):1545-1549.
9. Tiegs R.D., Lohse C.M., Wollan P.C., Melton L.J. Long-term trends in the incidence of Paget's disease of bone. Bone 2000, 27(3):423-427.
10. van Staa T.P., Selby P., Leufkens H.G., Lyles K., Sprafka J.M., Cooper C. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002, 17(3):465-471.
11. Guyer P.B., Chamberlain A.T. Paget's disease of bone in South Africa. Clin Radiol 1988, 39(1):51-52.
12. Alshaikh O.M., Almanea H., Alzahrani A.S. Paget disease of the bone: Does it exist in Saudi Arabia?. Ann Saudi Med 2011, 31(3):305-310.
13. Lowenthal M.N., Alkalay D., Abu Rabbia Y., Liel Y. Paget's disease of bone in Negev Bedouin: report of two cases. Isr J Med Sci 1995, 31(10):628-629.
14. Lee C.H., Han S.H., Yoon B.Y., Lee Y.W. Monostotic Paget's disease of the tibia in Korea. Clin Rheumatol 2004, 23(4):381-382.
15. H'Ng M.W., Ho Y.Y. Paget's disease of the bone in a Chinese woman. Australas Radiol 2005, 49(6):505-507.
16. Pompe Van Meerdervoort H.F., Richter G.G. Paget's disease of bone in South African Blacks. S Afr Med J 1976, 50(47):1897-1899.
17. Dahniya M.H. Paget's disease of bone in Africans. Br J Radiol 1987, 60(710):113-116.
18. Magen H., Liel Y., Bearman J.E., Lowenthal M.N. Demographic aspects of Paget's disease of bone in the Negev of southern Israel. Calcif Tissue Int 1994, 55(5):353-355.
19. Bloom R.A., Libson E., Blank P., Nubani N. Prevalence of Paget's disease of bone in hospital patients in Jerusalem: an epidemiologic study. Isr J Med Sci 1985, 21(12):954-956.
20. Dolev E, Samuel R, Foldes J, Brickman M, Assia A, Liberman UA. Some epidemiological aspects of Paget's disease of bone in Israel. Semin Arthritis Rheum 228;23(4):228.
21. Yip K.M., Lee Y.L., Kumta S.M., Lin J. The second case of Paget's disease (osteitis deformans) in a Chinese lady. Singapore Med J 1996, 37(6):665-667.
22. Hashimoto J., Ohno I., Nakatsuka K., Yoshimura N., Takata S., Zamma M., et al. Prevalence and clinical features of Paget's disease of bone in Japan. J Bone Miner Metab 2006, 24(3):186-190.
23. Kim G.S., Kim S.H., Cho J.K., Park J.Y., Shin M.J., Shong Y.K., et al. Paget bone disease involving young adults in 3 generations of a Korean family. Medicine (Baltimore) 1997, 76(3):157-169.
24. Gardner M.J., Guyer P.B., Barker D.J. Radiological prevalence of Paget's disease of bone in British migrants to Australia. BMJ 1978, 1(6128):1655-1657.
25. Laurin N., Brown J.P., Morissette J., Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002, 70(6):1582-1588.
26. Morissette J., Laurin N., Brown J.P. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006, 21(Suppl 2):P38-P44.
27. Selby P.L., Davie M.W., Ralston S.H., Stone M.D. Guidelines on the management of Paget's disease of bone. Bone 2002, 31(3):366-373.
28. Devogelaer J.P., Nagant de Deuxchaisnes C. Paget's disease of bone. Rheumatology 2003, vol. 2:2139-2147. Mosby, Toronto, Canada. 3rd ed. M.C. Hochberg, A.J. Silman, J.S. Smolen, M.E. Weinblatt, M.H. Weisman (Eds.).
29. Ralston S.H., Langston A.L., Reid I.R. Pathogenesis and management of Paget's disease of bone. Lancet 2008, 372(9633):155-163.
30. Neale S.D., Smith R., Wass J.A., Athanasou N.A. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 2000, 27(3):409-416.
31. Menaa C., Barsony J., Reddy S.V., Cornish J., Cundy T., Roodman G.D. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 2000, 15(2):228-236.
32. Menaa C., Reddy S.V., Kurihara N., Maeda H., Anderson D., Cundy T., et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000, 105(12):1833-1838.
33. Kurihara N., Reddy S.V., Araki N., Ishizuka S., Ozono K., Cornish J., et al. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's disease. J Bone Miner Res 2004, 19(7):1154-1164.
34. Rebel A., Malkani K., Basle M., Bregeon C. Nuclear inclusions in osteoclasts in Paget's bone disease. Calcif Tissue Res 1976, 21(Suppl):113-116.
35. Mills B.G., Singer F.R. Nuclear inclusions in Paget's disease of bone. Science 1976, 194(4261):201-202.
36. Harvey L., Gray T., Beneton M.N., Douglas D.L., Kanis J.A., Russell R.G. Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology. J Clin Pathol 1982, 35(7):771-779.
37. Howatson A.F., Fornasier V.L. Microfilaments associated with Paget's disease of bone: comparison with nucleocapsids of measles virus and respiratory syncytial virus. Intervirology 1982, 18(3):150-159.
38. Gherardi G., Lo Cascio V., Bonucci E. Fine structure of nuclei and cytoplasm of osteoclasts in Paget's disease of bone. Histopathology 1980, 4(1):63-74.
39. Roodman G.D., Windle J.J. Paget disease of bone. J Clin Invest 2005, 115(2):200-208.
40. Hansen M.F., Seton M., Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006, 21(Suppl 2):58-63.
41. Langston A.L., Campbell M.K., Fraser W.D., Maclennan G., Selby P., Ralston S.H. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007, 80(1):1-9.
42. Seton M., Moses A.M., Bode R.K., Schwartz C. Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011, 48(2):281-285.
43. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006, 12(1):17-25.
44. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15(6):457-475.
45. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., Pangrazio A., Susani L., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39(8):960-962.
46. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008, 83(1):64-76.
47. Bacri D., Arush M.W., Vlodavsky E., Kollander Y., Militianu D., Postovsky S. Osteogenic sarcoma in a child with familial expansile osteolysis syndrome: an accidental association?. J Pediatr Hematol Oncol 2010, 32(2):e50-e53.
48. Hughes A.E., Shearman A.M., Weber J.L., Barr R.J., Wallace R.G., Osterberg P.H., et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 1994, 3(2):359-361.
49. Hughes A.E., Ralston S.H., Marken J., Bell C., MacPherson H., Wallace R.G., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000, 24(1):45-48.
50. Crockett J.C., Mellis D.J., Scott D.I., Helfrich M.H. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 2011, 22(1):1-20.
51. Palenzuela L., Vives-Bauza C., Fernandez-Cadenas I., Meseguer A., Font N., Sarret E., et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. J Med Genet 2002, 39(10):E67.
52. Elahi E., Shafaghati Y., Asadi S., Absalan F., Goodarzi H., Gharaii N., et al. Intragenic SNP haplotypes associated with 84dup18 mutation in TNFRSF11A in four FEO pedigrees suggest three independent origins for this mutation. J Bone Miner Metab 2007, 25(3):159-164.
53. Johnson-Pais T.L., Singer F.R., Bone H.G., McMurray C.T., Hansen M.F., Leach R.J. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J Bone Miner Res 2003, 18(2):376-380.
54. Whyte M.P., Mills B.G., Reinus W.R., Podgornik M.N., Roodman G.D., Gannon F.H., et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res 2000, 15(12):2330-2344.
55. Whyte M.P. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann NY Acad Sci 2006, 1068:143-164.
56. Whyte M.P., Hughes A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002, 17(1):26-29.
57. Nakatsuka K., Nishizawa Y., Ralston S.H. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 2003, 18(8):1381-1385.
58. Ke Y.H., Yue H., He J.W., Liu Y.J., Zhang Z.L. Early onset Paget's disease of bone caused by a novel mutation (78dup27) of the TNFRSF11A gene in a Chinese family. Acta Pharmacol Sin 2009, 30(8):1204-1210.
59. Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgornik M.N., McAlister W.H., et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002, 347(3):175-184.
60. Cundy T., Hegde M., Naot D., Chong B., King A., Wallace R., et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002, 11(18):2119-2127.
61. Whyte M.P., Singhellakis P.N., Petersen M.B., Davies M., Totty W.G., Mumm S. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res 2007, 22(6):938-946.
62. Janssens K., de Vernejoul M.C., de Freitas F., Vanhoenacker F., Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone 2005, 36(3):542-548.
63. Chong B., Hegde M., Fawkner M., Simonet S., Cassinelli H., Coker M., et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003, 18(12):2095-2104.
64. Kimonis V.E., Fulchiero E., Vesa J., Watts G. VCP disease associated with myopathy. Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta 2008, 1782(12):744-748.
65. Kovach M.J., Waggoner B., Leal S.M., Gelber D., Khardori R., Levenstien M.A., et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy. Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001, 74(4):458-475.
66. Watts G.D., Wymer J., Kovach M.J., Mehta S.G., Mumm S., Darvish D., et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36(4):377-381.
67. Tresse E., Salomons F.A., Vesa J., Bott L.C., Kimonis V., Yao T.P., et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy 2010, 6(2):217-227.
68. Watts G.D., Thomasova D., Ramdeen S.K., Fulchiero E.C., Mehta S.G., Drachman D.A., et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007, 72(5):420-426.
69. Djamshidian A., Schaefer J., Haubenberger D., Stogmann E., Zimprich F., Auff E., et al. A novel mutation in the VCP gene (G157R) in a German family with inclusion-body myopathy with Paget disease of bone and frontotemporal dementia. Muscle Nerve 2009, 39(3):389-391.
70. Guyant-Marechal L., Laquerriere A., Duyckaerts C., Dumanchin C., Bou J., Dugny F., et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 2006, 67(4):644-651.
71. Haubenberger D., Bittner R.E., Rauch-Shorny S., Zimprich F., Mannhalter C., Wagner L., et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology 2005, 65(8):1304-1305.
72. Gordon M.T., Mee A.P., Anderson D.C., Sharpe P.T. Canine distemper virus transcripts sequenced from pagetic bone. Bone Miner 1992, 19(2):159-174.
73. Gordon M.T., Anderson D.C., Sharpe P.T. Canine distemper virus localised in bone cells of patients with Paget's disease. Bone 1991, 12(3):195-201.
74. Mee A.P., Dixon J.A., Hoyland J.A., Davies M., Selby P.L., Mawer E.B. Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction. Bone 1998, 23(2):171-175.
75. Selby P.L., Davies M., Mee A.P. Canine distemper virus induces human osteoclastogenesis through NF-kappaB and sequestosome 1/P62 activation. J Bone Miner Res 2006, 21(11):1750-1756.
76. Mills B.G., Singer F.R., Weiner L.P., Suffin S.C., Stabile E., Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop Relat Res 1984, (183):303-311.
77. Basle M.F., Fournier J.G., Rozenblatt S., Rebel A., Bouteille M. Measles virus RNA detected in Paget's disease bone tissue by in situ hybridization. J Gen Virol 1986, 67(Pt 5):907-913.
78. Reddy S.V., Singer F.R., Roodman G.D. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab 1995, 80(7):2108-2111.
79. Friedrichs W.E., Reddy S.V., Bruder J.M., Cundy T., Cornish J., Singer F.R., et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002, 17(1):145-151.
80. Reddy S.V., Singer F.R., Mallette L., Roodman G.D. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. J Bone Miner Res 1996, 11(11):1602-1607.
81. Mills B.G., Singer F.R., Weiner L.P., Holst P.A. Immunohistological demonstration of respiratory syncytial virus antigens in Paget disease of bone. Proc Natl Acad Sci USA 1981, 78(2):1209-1213.
82. Basle M.F., Russell W.C., Goswami K.K., Rebel A., Giraudon P., Wild F., et al. Paramyxovirus antigens in osteoclasts from Paget's bone tissue detected by monoclonal antibodies. J Gen Virol 1985, 66(Pt 10):2103-2110.
83. Ralston S.H., Digiovine F.S., Gallacher S.J., Boyle I.T., Duff G.W. Failure to detect paramyxovirus sequences in Paget's disease of bone using the polymerase chain reaction. J Bone Miner Res 1991, 6(11):1243-1248.
84. Nuovo M.A., Nuovo G.J., MacConnell P., Forde A., Steiner G.C. In situ analysis of Paget's disease of bone for measles-specific PCR-amplified cDNA. Diagn Mol Pathol 1992, 1(4):256-265.
85. Birch M.A., Taylor W., Fraser W.D., Ralston S.H., Hart C.A., Gallagher J.A. Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone. J Bone Miner Res 1994, 9(1):11-16.
86. Helfrich M.H., Hobson R.P., Grabowski P.S., Zurbriggen A., Cosby S.L., Dickson G.R., et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 2000, 15(12):2315-2329.
87. Ooi C.G., Walsh C.A., Gallagher J.A., Fraser W.D. Absence of measles virus and canine distemper virus transcripts in long-term bone marrow cultures from patients with Paget's disease of bone. Bone 2000, 27(3):417-421.
88. Ralston S.H., Hobson R.P., Pennington T.H., Helfrich M.H. Does Paget's disease really have a viral aetiology?. J Bone Miner Res 1997, 12(5):863-865.
89. Matthews B.G., Afzal M.A., Minor P.D., Bava U., Callon K.E., Pitto R.P., et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008, 93(4):1398-1401.
90. Mee A.P., May C., Bennett D., Sharpe P.T. Generation of multinucleated osteoclast-like cells from canine bone marrow: effects of canine distemper virus. Bone 1995, 17(1):47-55.
91. Mee A.P., Hoyland J.A., Baird P., Bennett D., Sharpe P.T. Canine bone marrow cell cultures infected with canine distemper virus: an in vitro model of Paget's disease. Bone 1995, 17(Suppl 4):461S-466S.
92. Kurihara N., Reddy S.V., Menaa C., Anderson D., Roodman G.D. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000, 105(5):607-614.
93. Reddy S.V., Kurihara N., Menaa C., Landucci G., Forthal D., Koop B.A., et al. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology 2001, 142(7):2898-2905.
94. Kurihara N., Zhou H., Reddy S.V., Garcia Palacios V., Subler M.A., Dempster D.W., et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2006, 21(3):446-455.
95. Kurihara N., Zhou H., Reddy S.V., Garcia Palacios V., Subler M.A., Dempster D.W., et al. Experimental models of Paget's disease. J Bone Miner Res 2006, 21(Suppl 2):55-57.
96. Gennari L., Gianfrancesco F., Di Stefano M., Rendina D., Merlotti D., Esposito T., et al. SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. J Bone Miner Res 2010, 25(6):1375-1384.
97. Siris E.S. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum 1994, 23(4):222-225.
98. Visconti M.R., Langston A.L., Alonso N., Goodman K., Selby P.L., Fraser W.D., et al. Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res 2010, 25(11):2368-2373.
99. Lever J.H. Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone 2002, 31(3):434-436.
100. Aono J., Yanagawa T., Itoh K., Li B., Yoshida H., Kumagai Y., et al. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem Biophys Res Commun 2003, 305(2):271-277.
101. Rogers J., Jeffrey D.R., Watt I. Paget's disease in an archeological population. J Bone Miner Res 2002, 17(6):1127-1134.
102. Reasbeck J.C., Goulding A., Campbell D.R., Beale L.R., Stewart R.D. Radiological prevalence of Paget's disease in Dunedin. New Zealand Br Med J (Clin Res Ed) 1937, 286(6382):1937.
103. Detheridge F.M., Guyer P.B., Barker D.J. European distribution of Paget's disease of bone. Br Med J (Clin Res Ed) 1982, 285(6347):1005-1008.
104. Lecuyer N., Grados F., Dargent-Molina P., Deramond H., Meunier P.J., Fardellone P. Prevalence of Paget's disease of bone and spinal hemangioma in French women older than 75 years: data from the EPIDOS study. Joint Bone Spine 2000, 67(4):315-318.
105. Eekhoff M.E., van der Klift M., Kroon H.M., Cooper C., Hofman A., Pols H.A., et al. Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey-the Rotterdam Study. J Bone Miner Res 2004, 19(4):566-570.
106. Ziegler R., Holz G., Rotzler B., Minne H. Paget's disease of bone in West Germany. Prevalence and distribution. Clin Orthop Relat Res 1985, 194:199-204.
107. Gennari L., Di Stefano M., Merlotti D., Giordano N., Martini G., Tamone C., et al. Prevalence of Paget's disease of bone in Italy. J Bone Miner Res 2005, 20(10):1845-1850.
108. Falch JA. Paget's disease in Norway. Lancet 1022;2(8150):1022.
109. Morales-Piga A.A., Rey-Rey J.S., Corres-Gonzalez J., Garcia-Sagredo J.M., Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995, 10(4):663-670.
110. Siris E.S., Ottman R., Flaster E., Kelsey J.L. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991, 6(5):495-500.
111. Sofaer J.A., Holloway S.M., Emery A.E. A family study of Paget's disease of bone. J Epidemiol Community Health 1983, 37(3):226-231.
112. Hocking L.J., Lucas G.J., Daroszewska A., Mangion J., Olavesen M., Cundy T., et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002, 11(22):2735-2739.
113. Laurin N., Brown J.P., Lemainque A., Duchesne A., Huot D., Lacourciere Y., et al. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 2001, 69(3):528-543.
114. Hocking L.J., Herbert C.A., Nicholls R.K., Williams F., Bennett S.T., Cundy T., et al. Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 2001, 69(5):1055-1061.
115. Cody J.D., Singer F.R., Roodman G.D., Otterund B., Lewis T.B., Leppert M., et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997, 61(5):1117-1122.
116. Fotino M., Haymovits A., Falk C.T. Evidence for linkage between HLA and Paget's disease. Transplant Proc 1977, 9(4):1867-1868.
117. Good D.A., Busfield F., Fletcher B.H., Duffy D.L., Kesting J.B., Andersen J., et al. Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 2002, 70(2):517-525.
118. Good D.A., Busfield F., Fletcher B.H., Lovelock P.K., Duffy D.L., Kesting J.B., et al. Identification of SQSTM1 mutations in familial Paget's disease in Australian pedigrees. Bone 2004, 35(1):277-282.
119. Haslam S.I., Van Hul W., Morales-Piga A., Balemans W., San-Millan J.L., Nakatsuka K., et al. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998, 13(6):911-917.
120. Hocking L., Slee F., Haslam S.I., Cundy T., Nicholson G., van Hul W., et al. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone 2000, 26(6):577-580.
121. Tilyard M.W., Gardner R.J., Milligan L., Cleary T.A., Stewart R.D. A probable linkage between familial Paget's disease and the HLA loci. Aust NZ J Med 1982, 12(5):498-500.
122. Lucas G.J., Riches P.L., Hocking L.J., Cundy T., Nicholson G.C., Walsh J.P., et al. Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent. J Bone Miner Res 2008, 23(1):58-63.
123. Lucas G.J., Hocking L.J., Daroszewska A., Cundy T., Nicholson G.C., Walsh J.P., et al. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J Bone Miner Res 2005, 20(2):227-231.
124. Falchetti A., Di Stefano M., Marini F., Ortolani S., Ulivieri M.F., Bergui S., et al. Genetic epidemiology of Paget's disease of bone in Italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone. Calcif Tissue Int 2009, 84(1):20-37.
125. Chung P.Y., Beyens G., Guanabens N., Boonen S., Papapoulos S., Karperien M., et al. Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's disease of bone. Calcif Tissue Int 2008, 83(1):34-42.
126. Rea S.L., Walsh J.P., Ward L., Yip K., Ward B.K., Kent G.N., et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006, 21(7):1136-1145.
127. Johnson-Pais T.L., Wisdom J.H., Weldon K.S., Cody J.D., Hansen M.F., Singer F.R., et al. Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. J Bone Miner Res 2003, 18(10):1748-1753.
128. Beyens G., Wuyts W., Cleiren E., de Freitas F., Tiegs R., Van Hul W. Identification and molecular characterization of a novel splice-site mutation (G1205C) in the SQSTM1 gene causing Paget's disease of bone in an extended American family. Calcif Tissue Int 2006, 79(5):281-288.
129. Falchetti A., Di Stefano M., Marini F., Del Monte F., Mavilia C., Strigoli D., et al. Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB). J Bone Miner Res 2004, 19(6):1013-1017.
130. Mossetti G., Gennari L., Rendina D., De Filippo G., Merlotti D., De Paola V., et al. Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. Calcif Tissue Int 2008, 83(6):414-424.
131. Roodman G.D. Insights into the pathogenesis of Paget's disease. Ann NY Acad Sci 2010, 1192:176-180.
132. Layfield R., Hocking L.J. SQSTM1 and Paget's disease of bone. Calcif Tissue Int 2004, 75(5):347-357.
133. Geetha T., Wooten M.W. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett 2002, 512(1-3):19-24.
134. Hershko A. Ubiquitin: roles in protein modification and breakdown. Cell 1983, 34(1):11-12.
135. Pickart C.M., Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004, 1695(1-3):55-72.
136. Cavey J.R., Ralston S.H., Hocking L.J., Sheppard P.W., Ciani B., Searle M.S., et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005, 20(4):619-624.
137. Ikeda F., Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep 2008, 9(6):536-542.
138. Thrower J.S., Hoffman L., Rechsteiner M., Pickart C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000, 19(1):94-102.
139. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005, 7(8):758-765.
140. Sanz L., Diaz-Meco M.T., Nakano H., Moscat J. The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 2000, 19(7):1576-1586.
141. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132(3):344-362.
142. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103(2):351-361.
143. Wooten M.W., Geetha T., Seibenhener M.L., Babu J.R., Diaz-Meco M.T., Moscat J. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 2005, 280(42):35625-35629.
144. Mizukami J., Takaesu G., Akatsuka H., Sakurai H., Ninomiya-Tsuji J., Matsumoto K., et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK. TAB2, and TRAF6. Mol Cell Biol 2002, 22(4):992-1000.
145. Lamothe B., Webster W.K., Gopinathan A., Besse A., Campos A.D., Darnay B.G. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun 2007, 359(4):1044-1049.
146. Besse A., Lamothe B., Campos A.D., Webster W.K., Maddineni U., Lin S.C., et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem 2007, 282(6):3918-3928.
147. Wu C.J., Conze D.B., Li T., Srinivasula S.M., Ashwell J.D. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006, 8(4):398-406.
148. Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430(7000):694-699.
149. Bignell G.R., Warren W., Seal S., Takahashi M., Rapley E., Barfoot R., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000, 25(2):160-165.
150. Komander D., Lord C.J., Scheel H., Swift S., Hofmann K., Ashworth A., et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008, 29(4):451-464.
151. Ang E., Pavlos N.J., Rea S.L., Qi M., Chai T., Walsh J.P., et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62. TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol 2009, 220(2):450-459.
152. Jin W., Chang M., Paul E.M., Babu G., Lee A.J., Reiley W., et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008, 118(5):1858-1866.
153. Saccani S., Marazzi I., Beg A.A., Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 2004, 200(1):107-113.
154. Arron J.R., Vologodskaia M., Wong B.R., Naramura M., Kim N., Gu H., et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001, 276(32):30011-30017.
155. Nakajima A., Sanjay A., Chiusaroli R., Adapala N.S., Neff L., Itzsteink C., et al. Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia. J Bone Miner Res 2009, 24(7):1162-1172.
156. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19(21):5720-5728.
157. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005, 171(4):603-614.
158. Yoshimori T. Autophagy: a regulated bulk degradation process inside cells. Biochem Biophys Res Commun 2004, 313(2):453-458.
159. Wooten M.W., Hu X., Babu J.R., Seibenhener M.L., Geetha T., Paine M.G., et al. Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62's role in neurodegenerative disease. J Biomed Biotechnol 2006, 2006(3):62079.
160. Terman A., Gustafsson B., Brunk U.T. Autophagy, organelles and ageing. J Pathol 2007, 211(2):134-143.
161. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137(4):721-735.
162. Wertz I.E., Dixit V.M. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ 2010, 17(1):14-24.
163. Hocking L.J., Lucas G.J., Daroszewska A., Cundy T., Nicholson G.C., Donath J., et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004, 19(7):1122-1127.
164. Ciani B., Layfield R., Cavey J.R., Sheppard P.W., Searle M.S. Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. J Biol Chem 2003, 278(39):37409-37412.
165. Cavey J.R., Ralston S.H., Sheppard P.W., Ciani B., Gallagher T.R., Long J.E., et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int 2006, 78(5):271-277.
166. Najat D., Garner T., Hagen T., Shaw B., Sheppard P.W., Falchetti A., et al. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res 2009, 24(4):632-642.
167. Rea S.L., Walsh J.P., Ward L., Magno A.L., Ward B.K., Shaw B., et al. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J Bone Miner Res 2009, 24(7):1216-1223.
168. Kurihara N., Hiruma Y., Zhou H., Subler M.A., Dempster D.W., Singer F.R., et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007, 117(1):133-142.
169. Duran A., Serrano M., Leitges M., Flores J.M., Picard S., Brown J.P., et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004, 6(2):303-309.
170. Hiruma Y., Kurihara N., Subler M.A., Zhou H., Boykin C.S., Zhang H., et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008, 17(23):3708-3719.
171. Kurihara N., Hiruma Y., Yamana K., Michou L., Rousseau C., Morissette J., et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011, 13(1):23-34.
172. Daroszewska A., van 't Hof R.J., Rojas J.A., Layfield R., Landao-Basonga E., Rose L., et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum Mol Genet 2011, 20(14):2734-2744.
173. Daroszewska A., Rojas J., Rose L., Van't Hof R.J., Ralston S.H. Knock-in of the P392L mutation of SQSTM1 causes a phenotype similar to Paget's disease in mice. Calcif Tissue Int 82:S34 2008.
174. Merchant A., Smielewska M., Patel N., Akunowicz J.D., Saria E.A., Delaney J.D., et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009, 24(3):484-494.
175. Matthews B.G., Naot D., Bava U., Callon K.E., Pitto R.P., McCowan S.A., et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009, 94(2):691-694.
176. Laurin N., Morissette J., Raymond V., Brown J.P. Large phenotypic variability of Paget disease of bone caused by the P392L sequestosome1/p62 mutation. Calcif Tissue Int 2003, 72:776.
177. Chamoux E., Couture J., Bisson M., Morissette J., Brown J.P., Roux S. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol 2009, 23(10):1668-1680.
178. Michou L., Morissette J., Gagnon E.R., Marquis A., Dellabadia M., Brown J.P., et al. Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population. Bone 2011, 48(3):456-460.
179. Bolland M.J., Tong P.C., Naot D., Callon K.E., Wattie D.J., Gamble G.D., et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007, 22(3):411-415.
180. Collet C., Michou L., Audran M., Chasseigneaux S., Hilliquin P., Bardin T., et al. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res 2007, 22(2):310-317.
181. Eekhoff E.W., Karperien M., Houtsma D., Zwinderman A.H., Dragoiescu C., Kneppers A.L., et al. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 2004, 50(5):1650-1654.
182. Beyens G., Van Hul E., Van Driessche K., Fransen E., Devogelaer J.P., Vanhoenacker F., et al. Evaluation of the role of the SQSTM1 gene in sporadic Belgian patients with Paget's disease. Calcif Tissue Int 2004, 75(2):144-152.
183. Chung P.Y., Beyens G., de Freitas F., Boonen S., Geusens P., Vanhoenacker F., et al. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. Mol Genet Metab 2011, 103(3):287-292.
184. Lucas G.J., Mehta S.G., Hocking L.J., Stewart T.L., Cundy T., Nicholson G.C., et al. Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone. Bone 2006, 38(2):280-285.
185. Donath J., Speer G., Poor G., Gergely P., Tabak A., Lakatos P. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget's disease of bone. Rheumatology (Oxford) 2004, 43(6):692-695.
186. Wuyts W., Van Wesenbeeck L., Morales-Piga A., Ralston S., Hocking L., Vanhoenacker F., et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001, 28(1):104-107.
187. Daroszewska A., Hocking L.J., McGuigan F.E., Langdahl B., Stone M.D., Cundy T., et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res 2004, 19(9):1506-1511.
188. Beyens G., Daroszewska A., de Freitas F., Fransen E., Vanhoenacker F., Verbruggen L., et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene. TNFRSF11B, and Paget's disease of bone. J Bone Miner Res 2007, 22(7):1062-1071.
189. Chung P.Y.J., Beyens G., Riches P.L., Van Wesenbeeck L., Jennes K., Daroszewska A., et al. Genetic variation in the TNFRSF11A (RANK) gene contributes to the risk to develop sporadic Paget's disease of bone. Bone 2009, 44(Suppl 2):S347-S348.
190. Chung P.Y., Beyens G., Riches P.L., Van Wesenbeeck L., de Freitas F., Jennes K., et al. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. J Bone Miner Res 2010, 25(12):2316-2329.
191. Albagha O.M., Visconti M.R., Alonso N., Langston A.L., Cundy T., Dargie R., et al. Genome-wide association study identifies variants at CSF1. OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010, 42(6):520-524.
192. Zhu G., Wu C.J., Zhao Y., Ashwell J.D. Optineurin negatively regulates TNFalpha-induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr Biol 2007, 17(16):1438-1443.
193. Chung P.Y., Beyens G., Boonen S., Papapoulos S., Geusens P., Karperien M., et al. The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1. OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet 2010, 128(6):615-626.
194. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005, 202(3):345-351.
195. Albagha O.M., Wani S.E., Visconti M.R., Alonso N., Goodman K., Brandi M.L., et al. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011, 10.1038/ng.845.
196. Hocking L.J., Mellis D.J., McCabe P.S., Helfrich M.H., Rogers M.J. Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts. Biochem Biophys Res Commun 2010, 402(3):543-548.
197. Lin H.K., Bergmann S., Pandolfi P.P. Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431(7005):205-211.
198. Smits P., Bolton A.D., Funari V., Hong M., Boyden E.D., Lu L., et al. Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210. N Engl J Med 2010, 362(3):206-216.
199. Hennies H.C., Kornak U., Zhang H., Egerer J., Zhang X., Seifert W., et al. Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet 2008, 40(12):1410-1412.
200. Sun S.G., Lau Y.S., Itonaga I., Sabokbar A., Athanasou N.A. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 2006, 209(1):114-120.
201. Polyzos S.A., Anastasilakis A.D., Efstathiadou Z., Kita M., Litsas I., Avramidis A., et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. Horm Metab Res 2009, 41(11):846-850.
202. Marshall M.J., Evans S.F., Sharp C.A., Powell D.E., McCarthy H.S., Davie M.W. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 2009, 42(10-11):965-969.
203. Naot D., Bava U., Matthews B., Callon K.E., Gamble G.D., Black M., et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007, 22(2):298-309.
204. Hoyland J.A., Freemont A.J., Sharpe P.T. Interleukin-6. IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Miner Res 1994, 9(1):75-80.
205. Price C.H., Goldie W. Paget's sarcoma of bone. A study of eighty cases from the Bristol and the Leeds bone tumour registries. J Bone Joint Surg Br 1969, 51(2):205-224.
206. Schajowicz F., Santini Araujo E., Berenstein M. Sarcoma complicating Paget's disease of bone. A clinicopathological study of 62 cases. J Bone Joint Surg Br 1983, 65(3):299-307.
207. Moore T.E., King A.R., Kathol M.H., El-Khoury G.Y., Palmer R., Downey P.R. Sarcoma in Paget disease of bone: clinical, radiologic, and pathologic features in 22 cases. AJR Am J Roentgenol 1991, 156(6):1199-1203.
208. Seret P., Basle M.F., Rebel A., Renier J.C., Saint-Andre J.P., Bertrans G., et al. Sarcomatous degeneration in Paget's bone disease. J Cancer Res Clin Oncol 1987, 113(4):392-399.
209. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance. Epidemiology, and End Results Program. Cancer 2009, 115(7):1531-1543.
210. Porretta C.A., Dahlin D.C., Janes J.M. Sarcoma in Paget's disease of bone. J Bone Joint Surg Am 1957, 39A(6):1314-1329.
211. Price C.H. The incidence of osteogenic sarcoma in South-West England and its relationship to Paget's disease of bone. J Bone Joint Surg Br 1962, 44B:366-376.
212. Mirabello L., Troisi R.J., Savage S.A. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009, 125(1):229-234.
213. Mangham D.C., Davie M.W., Grimer R.J. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Bone 2009, 44(3):431-436.
214. Deyrup A.T., Montag A.G., Inwards C.Y., Xu Z., Swee R.G., Krishnan Unni K. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med 2007, 131(6):942-946.
215. Lake M. Studies of Paget's disease (osteitis deformans). J Bone Joint Surg Br 1951, 33B(3):323-335.
216. Shaylor P.J., Peake D., Grimer R.J., Carter S.R., Tillman R.M., Spooner D. Paget's Osteosarcoma-no cure in sight. Sarcoma 1999, 3(3-4):191-192.
217. Hoch B., Hermann G., Klein M.J., Abdelwahab I.F., Springfield D. Giant cell tumor complicating Paget disease of long bone. Skeletal Radiol 2007, 36(10):973-978.
218. Potter H.G., Schneider R., Ghelman B., Healey J.H., Lane J.M. Multiple giant cell tumors and Paget disease of bone: radiographic and clinical correlations. Radiology 1991, 180(1):261-264.
219. Hoyland J., Sharpe P.T. Upregulation of c-fos protooncogene expression in pagetic osteoclasts. J Bone Miner Res 1994, 9(8):1191-1194.
220. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319(9):525-532.
221. Haber D.A., Buckler A.J., Glaser T., Call K.M., Pelletier J., Sohn R.L., et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990, 61(7):1257-1269.
222. Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., Saulino A.M., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249(4965):181-186.
223. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323(6089):643-646.
224. Fung Y.K., Murphree A.L., T'Ang A., Qian J., Hinrichs S.H., Benedict W.F. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987, 236(4809):1657-1661.
225. Hansen M.F., Koufos A., Gallie B.L., Phillips R.A., Fodstad O., Brogger A., et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 1985, 82(18):6216-6220.
226. Yamaguchi T., Toguchida J., Yamamuro T., Kotoura Y., Takada N., Kawaguchi N., et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992, 52(9):2419-2423.
227. Nellissery M.J., Padalecki S.S., Brkanac Z., Singer F.R., Roodman G.D., Unni K.K., et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 1998, 63(3):817-824.
228. Johnson-Pais T.L., Nellissery M.J., Ammerman D.G., Pathmanathan D., Bhatia P., Buller C.L., et al. Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. Int J Cancer 2003, 105(2):285-288.
229. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009, 119(4):837-851.
230. Forbes S.A., Bhamra G., Bamford S., Dawson E., Kok C., Clements J., et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008, Chapter 10, Unit 10, 11.
231. Devogelaer J.P., Bergmann P., Body J.J., Boutsen Y., Goemaere S., Kaufman J.M., et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int 2008, 19(8):1109-1117.
232. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19(6):733-759.
233. Altman R.D., Johnston C.C., Khairi M.R., Wellman H., Serafini A.N., Sankey R.R. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973, 289(26):1379-1384.
234. Ralston S.H., Boyce B.F., Cowan R.A., Fogelman I., Smith M.L., Jenkins A., et al. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease-a double-blind randomized clinical study. J Bone Miner Res 1987, 2(1):5-12.
235. Fraser W.D., Stamp T.C., Creek R.A., Sawyer J.P., Picot C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997, 73(862):496-502.
236. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005, 353(9):898-908.
237. Langston A.L., Campbell M.K., Fraser W.D., MacLennan G.S., Selby P.L., Ralston S.H. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 2010, 25(1):20-31.
238. Mahmood W., McKenna M.J. Proposed new approach for treating Paget's disease of bone. Ir J Med Sci 2010, 180(1):121-124.
239. Boonen S., Laan R.F., Barton I.P., Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005, 16(10):1291-1298.
240. Hamdy R.C. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther 2010, 4:321-335.
241. Sunyecz J.A. Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Womens Health 2010, 2:353-360.
242. Cauley J.A., Black D., Boonen S., Cummings S.R., Mesenbrink P., Palermo L., et al. Once-yearly zoledronic acid and days of disability, bed rest and back pain: Randomised controlled HORIZON pivotal fracture trial. J Bone Miner Res 2010, 10.1002/jbmr.292.
243. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99(4):322-330.
244. Sirohi B., Powles R. Multiple myeloma. Lancet 2004, 363(9412):875-887.
245. Coleman R.E. Bisphosphonates in breast cancer. Ann Oncol 2005, 16(5):687-695.
246. Parker C.C. The role of bisphosphonates in the treatment of prostate cancer. BJU Int 2005, 95(7):935-938.
247. Murayama T., Kawasoe Y., Yamashita Y., Ueno Y., Minami S., Yokouchi M., et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 2008, 28(4B):2147-2154.
248. Xin Z.F., Kim Y.K., Jung S.T. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 2009, 28:105.
249. Graham D.Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002, 47(8):1665-1678.
250. Lanza F.L., Hunt R.H., Thomson A.B., Provenza J.M., Blank M.A. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000, 119(3):631-638.
251. Thomson A.B., Marshall J.K., Hunt R.H., Provenza J.M., Lanza F.L., Royer M.G., et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002, 29(9):1965-1974.
252. Gallacher S.J., Ralston S.H., Patel U., Boyle I.T. Side-effects of pamidronate. Lancet 1989, 2(8653):42-43.
253. Thompson K., Michael J.R. Bisphosphonates and γδ T-cells: new insights into old drugs. BoneKEy-Osteovision 2006, 3(8):5-13.
254. Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19(2):278-288.
255. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
256. Hoefert S., Schmitz I., Tannapfel A., Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010, 14(3):271-284.
257. Burr D.B., Allen M.R. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 2009, 12(3):221-228.
258. French D.D., Margo C.E. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008, 28(6):889-893.
259. Fraunfelder F.W., Fraunfelder F.T., Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003, 135(2):219-222.
260. Richards J.C., Wiffen S.J. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea 2006, 25(9):1100-1101.
261. Markowitz G.S., Fine P.L., Stack J.I., Kunis C.L., Radhakrishnan J., Palecki W., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003, 64(1):281-289.
262. Markowitz G.S., Appel G.B., Fine P.L., Fenves A.Z., Loon N.R., Jagannath S., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001, 12(6):1164-1172.
263. Pageau S.C. Denosumab. MAbs 2009, 1(3):210-215.
264. Miller P.D., Wagman R.B., Peacock M., Lewiecki E.M., Bolognese M.A., Weinstein R.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011, 96(2):394-402.
265. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 2011, 48(4):677-692.